Trial site
Baoji Central Hospital
Baoji, Shanxi 721008, ChinaNot linked to an institution yet
- 14running trials
- 3closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 1/21 trial
- Phase 21 trial
- Status
- Active, not recruiting6 trials
- Not yet recruiting4 trials
- Recruiting4 trials
- Completed3 trials
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.5 trials
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.2 trials
- Akeso1 trial
- Bayer1 trial
- Boehringer Ingelheim1 trial
- and 7 more
Running trials
Recruiting
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07564596· Phase 1/2· Climb Bio, Inc.· Source
Contact: Climb Bio Investigate Site 12
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Yayu Zhao, Doctor
Recruiting
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Kai Chen, Master
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Kai Chen, Master
Active, not recruiting
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source
Not yet recruiting
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).
NCT06606509· Nanjing First Hospital, Nanjing Medical University· Source
Contact: Lifen Ma, Doctor
Active, not recruiting
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886· Phase 3· Hoffmann-La Roche· Source
Recruiting
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT05862337· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Gang Wang, Bachelor
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Not yet recruiting
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
NCT04995159· Lepu Medical Technology (Beijing) Co., Ltd.· Source
Contact: Yuhu Chun
Active, not recruiting
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
NCT04344158· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error